Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMblaze370: Atezolizumab +/- Cobimetinib vs Regorafenib in mCRC
NCT02788279Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2016
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Roche. Primary endpoint: Overall Survival at 20 months. Started Jul 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02788279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788279.